Hemorheological-hemostatic findings may serve as valuable surrogate endpoints in clinical trials evaluating lipid-lowering therapies in dyslipidemic patients.
Answers are grounded in this paper and cite their sources.
Caution against clinical use of these markers in dyslipidemia; leaves open their value as trial surrogates pending validation.
High levels of plasma lipids have been recognized as a major risk factor in the development and progression of atherosclerosis, and to influence hemorheological factors that may predispose to thrombotic complications. Lipid-lowering interventions have been associated with a significant reduction of morbidity and mortality. Several mechanisms have been postulated for the observed clinical effect. Serum lipid-regulating therapies may reduce cardiovascular risk not only by altering the arterial wall, improving disturbed endothelial function, atherogenesis and plaque stability, but also through their antithrombogenic effects and influence on blood flow properties associated with hyperlipidemia. In this article, we will review the recent literature and discuss the value of hemorheological-hemostatic findings as surrogate endpoints for clinical trials in dyslipidemic patients.
No takes yet. Share an insight, caveat, or question.
Corti et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: